CRISPR-Cas9 and the non-germline non-controversy
Authors:
Open Access
- 11 June 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Law and the Biosciences
- Vol. 3 (2) , 413-425
Abstract
On April 5, 2015, the first genome editing of human embryos was reported. The genome of an organism is the sum total of its DNA; to edit a genome is to make a highly specific change to it. The paper, by a group of Chinese researchers, used a new technology known as CRISPR-Cas9 (the embryos in question were intentionally chosen to be non-viable). This application came just three years after the technology's genesis.1 Although the possibility of modifying genomes had been around for several decades, CRISPR-Cas9 is on the verge of making this a much more powerful reality. Not only is the technology effective, it is also very low cost and accessible.Keywords
This publication has 6 references indexed in Scilit:
- Wavefront-guided versus wavefront-optimized photorefractive keratectomy: Clinical outcomes and patient satisfactionJournal of Cataract & Refractive Surgery, 2015
- Safety and efficacy of wavefront-guided myopic laser in situ keratomileusis using a new wavefront sensor technology: First 100 casesJournal of Cataract & Refractive Surgery, 2015
- Prevalence of Ulnar Collateral Ligament Surgery in Professional Baseball PlayersThe American Journal of Sports Medicine, 2015
- Cochlear implantation in the world's largest medical device market: Utilization and awareness of cochlear implants in the United StatesCochlear Implants International, 2013
- Genome-wide association and longitudinal analyses reveal genetic loci linking pubertal height growth, pubertal timing and childhood adiposityHuman Molecular Genetics, 2013
- Deafness, culture, and choiceJournal of Medical Ethics, 2002